Update to Resiliency Roadmap for FDA Inspectional Oversight - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. Update to Resiliency Roadmap for FDA Inspectional Oversight Today, FDA released an update to the "Resiliency Roadmap for FDA Inspectional Oversight" report. As of September 30, 2021, FDA has exceeded the Base-Case Scenario projections for FY21, completing more than twice as many domestic surveillance oversight activities than projected in the Roadmap. FDA's development of new oversight approaches and expanded use of a variety of surveillance tools significantly contributed to the agency's ability to exceed these goals. This enabled the agency to provide oversight to as many facilities as possible, while utilizing our resources to protect consumers and patients and promote public health. Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA